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ABSTRACT 31 
Aims. Pulmonary hypertension (PH) is associated with high morbidity and mortality and the 32 
predictive capacity of traditional functional echocardiographic measures is poor. Recent 33 
studies assessed the predictive capacity of right ventricular longitudinal strain (RVLS). 34 
Diversity in methods between these studies resulted in conflicting outcomes. The purpose of 35 
this systematic review and meta-analysis was to determine the independent prognostic value 36 
of RVLS for PH-related events and all-cause mortality.  37 
Methods and results. A systematic search in Pubmed (MEDLINE), Embase, the Cochrane 38 
Library and Web of Science was performed to identify studies that examined the prognostic 39 
value of RVLS in patients with PH. Studies reporting Cox regression based Hazard Ratios 40 
(HR) for a combined endpoint of mortality and PH-related events or all-cause mortality for 41 
echocardiographic derived RVLS were included. A weighted mean of the multivariate HR 42 
was used to determine the independent predictive value of RVLS.  43 
Eleven studies met our criteria, including 1,169 patients with PH (67% female, 0.6-3.8 years 44 
follow-up). PH patients with a relative reduction of RVLS of 19% had a significantly higher 45 
risk for the combined endpoint (HR: 1.22, 95%CI: 1.07-1.40), while patients with a relative 46 
reduction of RVLS of 22% had a significantly higher risk for all-cause mortality (HR: 2.96, 47 
95%CI: 2.00-4.38).  48 
Conclusion. This systematic review and meta-analysis showed that RVLS has independent 49 
prognostic value for a combined endpoint and all-cause mortality in patients with PH. 50 
Collectively, these findings emphasize that RVLS may have value for optimizing current 51 
predictive models for clinical events or mortality in patients with PH. 52 
 53 
KEYWORDS:  Right ventricular longitudinal strain, pulmonary hypertension, prognostic 54 
value, echocardiography 55 
 56 
 57 
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INTRODUCTION 58 
Pulmonary hypertension (PH) is a progressive disease with a 5-year survival rate of 59 
approximately 50%, depending on aetiology and disease severity.(1) Although the aetiology 60 
of PH relates to an increased pulmonary artery resistance, the primary cause of death relates 61 
to right ventricular (RV) failure since the RV has to overcome the increased pulmonary 62 
resistance in order to maintain cardiac output.(2) Consequently, echocardiographic 63 
measurements of RV structure and function are routinely performed during follow-up of 64 
patients with PH.(3, 4) Due to complex RV geometry and load dependency of the RV 65 
functional parameters, traditional echocardiographic indices such as RV fractional area 66 
change (RVFAC) and tricuspid annular plane systolic excursion (TAPSE), have limited 67 
prognostic power in patients with PH.(3) 68 
 69 
The introduction of speckle tracking echocardiography has allowed for the measurement of 70 
ventricular longitudinal strain, a measure of ventricular deformation to assess specific local 71 
and global function.(5) In heart failure, valvular heart disease, cardiomyopathy and ischaemic 72 
heart disease, left ventricular longitudinal strain independently predicts future events.(6) 73 
Patients with PH demonstrate a reduced RV longitudinal strain (RVLS) compared to healthy 74 
controls, whilst several studies have examined the prognostic value of RVLS in patients with 75 
PH.(7-30) These studies report a broad range of outcomes, ranging from no significant 76 
predictive capacity to a high predictive capacity. These differences in outcome may relate to 77 
differences in methodology between studies, such as variation in aetiology (PH vs pulmonary 78 
arterial hypertension (PAH)), included population for HR calculation (inclusion of healthy 79 
controls or non PH patient vs just PH patients), patient management at time of inclusion 80 
(treatment naive vs. single or combined therapy), follow-up duration (0.6-5.0 years), outcome 81 
parameters (morbidity vs all-cause mortality), group size (n=17 up to n=406) and methods in 82 
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which the HRs were determined (percentile change (continuous parameter) vs a predefined 83 
cut-off point (dichotomous parameter)).(7-11, 14-17, 21, 23, 24, 28, 29) The heterogeneity in 84 
study designs and outcomes provide a challenge when attempting to establish the potential 85 
prognostic value of RVLS in patients with PH. Combining these studies in a systematic 86 
review and meta-analysis will provide clarity on the prognostic value of RVLS in patients 87 
with PH. 88 
 89 
The purpose of this systematic review and meta-analysis was to determine the independent 90 
prognostic value of RVLS in patients with PH on PH-related events and all-cause mortality. 91 
We hypothesize that RVLS will have independent prognostic value in PH patients for PH-92 
related events and all-cause mortality. 93 
 94 
METHODS 95 
Search strategy 96 
A systematic search was performed with the use of the Preferred Reporting Items for 97 
Systematic Reviews and Meta-Analysis statement 2015 (PRISMA).(31) Pubmed 98 
(MEDLINE), Embase, the Cochrane Library and Web of Science were systematically 99 
searched for articles published before February 1th, 2018. The following search strategy was 100 
used, with adaptation for each database: (((("Hypertension, Pulmonary"[Mesh]) OR 101 
((Pulmonary hypertension[tiab] OR Pulmonary artery hypertension[tiab] OR Pulmonary 102 
arterial hypertension[tiab] OR PAH[tiab] OR lung arterial hypertension[tiab] OR lung artery 103 
hypertension[tiab] OR lung hypertension[tiab])))) AND ((strain[tiab] OR deformation[tiab]))) 104 
AND ((("Prognosis"[Mesh] OR "Survival Analysis"[Mesh] OR "Mortality"[Mesh] OR 105 
"mortality"[Subheading] OR "Hospitalization"[Mesh])) OR (Prognos*[tiab] OR Predict*[tiab] 106 
OR Surviv*[tiab] OR Mortalit*[tiab] OR Hazard ratio*[tiab] OR Hospitalization[tiab] OR 107 
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Hospitalisation[tiab])). References of included articles were manually checked for possible 108 
eligible studies that were missed during the literature search. 109 
 110 
Study selection 111 
After the initial search, duplicates were eliminated from the database. Two authors (H.H., 112 
G.K.) independently screened the remaining study titles and abstracts for eligibility using the 113 
predefined inclusion and exclusion criteria (Table 1), resulting in 42 articles from which full 114 
text was assessed (Fig. 1). We included studies in which either RV free wall longitudinal 115 
strain (RVFWS) or RV global longitudinal strain (RVGLS) was evaluated as a predictor for a 116 
combined endpoint of mortality and PH-related events or (all-cause) mortality. We excluded 117 
those studies, which did not perform Cox proportional hazard ratio analysis, or if the 118 
(independent) prognostic value of RVLS in PH patients was not reported. Additionally in 119 
order to ensure we determine the independent prognostic value of RVLS in patients with PH 120 
only, we excluded studies which performed Cox proportional hazard ratio analysis in a 121 
population which included non PH patients (i.e. healthy controls or suspected patients).  122 
 123 
Data extraction   124 
Data was independently extracted by two authors (H.H. and G.K.) using a predetermined data 125 
extraction file. Differences in data extraction were resolved by consensus and if necessary a 126 
third author was consulted (T.E.). Since all selected studies included strain, but only one study 127 
stain and strain rate, we focused on the prognostic value of strain only. Univariate and 128 
multivariate HR (95%-CI), the mean RVLS for the study population and the RVLS cutoff 129 
value for calculation of the HR were extracted from the individual studies (Table 2). The 130 
included studies reported HRs on either a continuous scale (i.e. change in risk per % RVLS) 131 
and/or a dichotomous scale (i.e. below/above a cut-off point). In case of a dichotomous scale 132 
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the HR should increase with a higher absolute value (due to the negative nature of RVLS), but 133 
as some studies investigated the beneficial effect of a RVLS value below a certain cut-off 134 
point, we calculated the inverse HR (1/HR – [1/95%-CI]) to ensure homogeneous presentation 135 
of the data. Additional information gathered consisted of: sample size, age, sex, World Health 136 
Organisation (WHO) class, New York Heart Association (NYHA) class, the follow-up period 137 
and the clinical endpoint of the individual studies (Table 3). For assessment of study quality, 138 
data regarding the echocardiographic assessment was gathered consisting of manufacturer, 139 
assessment software, echocardiographic window / image, included segments, methods of 140 
optimization and usage of the guidelines. When viable data was missing, an attempt was made 141 
to request missing data from the authors by email (n=4 studies). Three out of four studies with 142 
missing data provided the requested information and were included in our meta-analysis 143 
(Figure 1).  144 
 145 
Study quality 146 
All studies included in our meta-analysis were assessed for quality using the Quality In 147 
Prognosis Studies (QUIPS) checklist for measuring study quality by two authors (H.H. and 148 
G.K.).(32) The QUIPS checklist exists of 31 items divided over six domains; study 149 
participation, study attrition, prognostic factor measurement, outcome measurement, study 150 
confounding and statistical analysis and reporting. For each domain, several items were 151 
evaluated after which the domain was scored for the presence of low, moderate or high risk of 152 
bias. As recommended, a predefined overall rating was applied.(32) Studies with a high risk 153 
of bias score in a single domain or ≥3 scores of moderate risk of bias in different domains 154 
were rated as high risk of bias and excluded from this review (Supplementary Table 1). 155 
 156 
Echocardiographic assessment 157 
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To ensure high quality and consistency of the RVLS measurement we only included studies 158 
which reported adherence to the ASE guidelines for echocardiographic assessment of the right 159 
heart(33) and/or chamber quantification(34), used a (focused) RV apical 4 chamber view and 160 
traced the endocardial border for RVLS determination. 161 
 162 
Statistical analysis 163 
Review Manager 5.3 (Cochrane Community) was used to perform a meta-analysis of the 164 
reported multivariate HRs. The reported HRs [95%-CI] were converted to a log (HR) and the 165 
complementing standard error (SE) using the formula: 166 
𝑆𝐸 =
ln(𝑢𝑝𝑝𝑒𝑟 𝑏𝑜𝑢𝑛𝑑𝑎𝑟𝑦 (95% − 𝐶𝐼)) − ln(𝑙𝑜𝑤𝑒𝑟 𝑏𝑜𝑢𝑛𝑑𝑎𝑟𝑦 (95% − 𝐶𝐼))
(2 ∗ 1.96)
 167 
The resulting values were inserted in the inverse variance method for calculation of HRs 168 
using a random effects analysis to calculate the mean weighted HR [95% CI] for all studies. 169 
Separate analysis were performed for 1) a combined endpoint of mortality and PH-related 170 
events and 2) all-cause mortality. To provide further insight in the relation between RVLS and 171 
the risk for the combined endpoint or all-cause mortality, we calculated the relative reduction 172 
of RVLS (in %) for which the HR was determined. For this purpose, we defined the relative 173 
reduction of RVLS as: the difference between the mean RVLS of the PH patients above the 174 
cut-off point and the cut-off point (for dichotomous scales) or between the mean RVLS of the 175 
PH patients and the chosen amount of change in % strain (for continuous scales). The 176 
weighted mean relative reduction in RVLS and follow-up time was calculated by multiplying 177 
the relative % reduction of RVLS or months of follow-up with the number of included 178 
patients per study, after which the cumulative value was divided by the total number of 179 
patients included in each analysis. 180 
 181 
RESULTS 182 
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Study selection 183 
During our search we identified 1,558 potential articles for inclusion. After removal of 184 
duplicates, 1,155 articles remained, from which title and abstract were screened for potential 185 
inclusion. Finally, a total of 42 studies were considered to be eligible for inclusion (Figure 1). 186 
After carefully reading through the full-texts, we identified 12 studies that met our inclusion 187 
criteria.(7-11, 14, 15, 21, 23, 26, 28, 29) From these 12 studies, six provided data on all-cause 188 
mortality(9, 10, 14, 15, 23, 28), from which one study did not report nor provide the results of 189 
multivariate analysis.(14) This study was therefore excluded from our meta-analysis. Seven 190 
studies reported data for the combined endpoint.(7, 8, 10, 11, 21, 26, 29) One study reported 191 
separate data for all-cause mortality and combined endpoint and was included for both 192 
analysis.(10) The remaining 11 studies included a total number of 1,169 patients with PH. 193 
Studies included predominantly female patients (range: 56-83%), with a mean age varying 194 
from 39 to 66 years. Details about the patient population, WHO class, NYHA class and study 195 
design of studies that were included are summarized in Table 3. 196 
 197 
Study endpoints 198 
Studies that examined the combined endpoint included 821 patients with PH, with a follow-up 199 
time ranging from 0.6-3.8 years. PH-related events varied from hospitalizations for worsening 200 
of PH(7, 8, 10, 21), lung transplantation(8, 10, 26), atrial septostomy(8), pulmonary 201 
endarterectomy(21), balloon pulmonary angioplasty(21) and intensified PH medical 202 
therapy.(8, 11) Studies that explored all-cause mortality as the primary endpoint included a 203 
total of 399 patients with PH, with a follow-up time ranging from 2.0-3.8 years. 204 
 205 
Echocardiographic assessment 206 
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All studies reported that strain was calculated from 2D or 3D grey scale apical 4-chamber 207 
orientation, whilst one study performed both 2D and 3D-strain imaging.(28). Strain was 208 
calculated with a variety of software packages (EchoPAC, GE Medical Systems, n=8; Syngo 209 
vector velocity imaging, Siemens, n=2; 2D cardiac performance analysis, TomTec, n=1). 10 210 
out of 11 studies determined a multivariate HR for RVFWS, while 4 out of 11 studies 211 
determined the multivariate HR for RVGLS. Half of the studies (6 out of 11) reported the 212 
methods applied for image optimization (i.e. adjustment of image sector width, gain and 213 
greyscale), while 9 out of 11 studies reported a frame-rate of >40 frames/s for strain analysis. 214 
 215 
Combined endpoint 216 
Seven studies adopted a combined endpoint of mortality and PH-related events and had a 217 
mean follow-up time of 26±17 months.(7, 8, 10, 11, 21, 26, 29) All but one (26) study 218 
revealed a significant HR after univariate analysis. After multivariate analysis, four studies 219 
revealed a significant HR for mortality and PH-related events(7, 8, 10, 26), while HR did not 220 
achieve statistical significance in three studies.(11, 21, 29) Combining all multivariate HRs in 221 
our meta-analysis revealed that a relative reduction of 19% (range -5 to -31%) of RVLS 222 
significantly increased the risk (HR: 1.22, 95%CI: 1.07-1.40) for the combined endpoint of 223 
mortality and PH-related events (Figure 2).  Studies with a relative reduction below 10% of 224 
RVLS tended to be insignificant after multivariate analysis while studies with a relative 225 
reduction larger than 10% of RVLS did present significantly higher HR’s after multivariate 226 
analysis (Figure 2). 227 
 228 
All-cause mortality 229 
Using data from univariate analysis, all five studies revealed a significant increased HR for 230 
RVLS in the prediction for future all-cause mortality after a mean follow-up time of 30±9 231 
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months. Multivariate analysis revealed that a lower RVLS was associated with a significantly 232 
higher HR for all-cause mortality in all studies.(9, 10, 15, 23, 28)  Combining all multivariate 233 
HRs, our meta-analysis revealed that a relative reduction of 22% (range -10 to -33%) of 234 
RVLS was associated with an increased risk (HR: 2.96, 95%CI: 2.00-4.38) for all-cause 235 
mortality (Figure 3). No clear relation between a larger relative reduction in % of RVLS and 236 
HR was present (Figure 3). 237 
 238 
 239 
DISCUSSION 240 
The purpose of this systematic review and meta-analysis was to examine whether RVLS has 241 
prognostic value for future events in patients with PH. The key finding was that RVLS has 242 
independent prognostic value for all-cause mortality (Figure 3). To a lesser extent, RVLS also 243 
demonstrated independent predictive capacity for the combined endpoint of mortality and PH-244 
related events (Figure 2). Collectively, these findings emphasize that RVLS is a valuable tool 245 
with independent prognostic value for all-cause mortality in PH patients.  246 
 247 
Impact of PH on RVLS 248 
The thin RV walls consist of longitudinal, circumferential and oblique oriented muscle 249 
fibers.(35) The free wall predominantly consists of transverse fibers with scanty 250 
subendocardial longitudinal oriented fibers, while in the septal wall the oblique fibers are in a 251 
helical shape.(35) Coiling and shortening of the helical-shaped oblique fibers determine the 252 
shortening of the RV, producing 80% of RV systolic function. In contrast, contraction of the 253 
transverse fibers accounts for just 20% of RV systolic function.(35) In a healthy RV, 254 
contraction is therefore predominantly driven by shortening of the RV in the longitudinal 255 
direction (35, 36), highlighting the importance of examining RVLS(35) in clinical and 256 
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research scenarios. In PH, an increase in afterload influences the mechanical function of the 257 
RV, which subsequently leads to a decrease in longitudinal shortening (37), indicating 258 
insufficient contraction and leading to a reduction of RV stroke volume. The increased 259 
afterload forces the RV to adapt, causing either hypertrophy and/or increased contractility to 260 
preserve function and stroke volume.(38) Ultimately, however, these processes may lead to 261 
maladaptive remodelling, which causes dilation of the chamber and altering of the helical 262 
orientation of the oblique fibers, leading to (progressive) attenuation of function.(35) This 263 
maladaptive process ultimately contributes to clinical progression and/or mortality. The strong 264 
relation between an increase in afterload and/or ventricular maladaptation alongside a 265 
decrease in RVLS likely explains the strong and independent prognostic value for RVLS for 266 
all-cause mortality in PH patients. 267 
 268 
All-cause mortality vs. combined endpoint 269 
Our meta-analysis revealed a lower predictive capacity for combined endpoints versus all-270 
cause mortality. This difference may be explained by the fact that clinical events included in 271 
the analysis for the combined endpoint are heterogeneous and, therefore, not all events may 272 
directly relate to strain (hence, the lower predictive capacity). Other factors than cardiac strain 273 
(e.g. gas transfer in the lungs(39)) may contribute to the occurrence of these clinical events. In 274 
addition, several studies included intensified PH medical therapy as a combined endpoint, 275 
whilst this unlikely relates to cardiac strain. Therefore, the diversity in clinical events included 276 
in the combined endpoint, but also the weak link between some of these factors and cardiac 277 
strain, lowers the discriminating capacity of RVLS to predict a combined endpoint versus all-278 
cause mortality.  279 
 280 
Predictive capacity vs. a relative reduction in % of RVLS  281 
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As shown in Figure 3 there is no clear relation between the relative reduction in % of RVLS 282 
and the HR for all-cause mortality. This may be explained by the differences across study 283 
designs. In contrast to our expectations, the three studies with the lowest relative reduction in 284 
RVLS presented the highest HRs in the analysis for all-cause mortality. These three studies all 285 
used a dichotomous cut-off value (between -17% and -20%) for RVLS(9, 15, 28), which was 286 
higher than the mean RVLS value for the PH patients in the two remaining studies (i.e. -287 
16.1% and -15%).(10, 23) The latter two studies calculated the HR per SD-unit change in 288 
RVLS, which resulted in a lower absolute cut-off (approximately -11.1 and -10%) value and 289 
in a higher incidence of mortality in the group above the cut-off value. In contrast to the cut-290 
off values in the latter two studies, additional analysis to identify the ideal cut-off value in 4 291 
out of these 5 studies showed that an absolute cut-off between -12.5% and -19.1% had the 292 
highest sensitivity and specificity to detect all-cause mortality in PH patients.(9, 10, 23, 28) 293 
This indicates that the calculated HR per SD-unit change underestimates the predictive value 294 
of RVLS in the latter two studies.  295 
 296 
Future direction and clinical implications. Outcomes of the present meta-analysis supports 297 
the use of RVLS in patients with PH. Although RVLS has independent predictive value, 298 
recent strategies for predicting mortality and events in PH patients consists of constructing 299 
multi-parameter predictive models(40) including TAPSE and/or RFVAC to increase the 300 
predictive value in PH patients.(3, 41) Several studies included in our meta-analysis revealed 301 
RVLS to has superior predictive value over RVFAC and TAPSE, indicating that RVLS may 302 
be a more sensitive predictor for RV dysfunction.(8, 10, 15) Implementing RVLS in these 303 
multi-parameter predictive models therefore may increase their predictive value for future 304 
events. In addition to predicting future events, a relative reduction in RVLS might be 305 
indicative for (adjustment of) pharmacological therapy and/or surgery. Improvement of RVLS 306 
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after pharmacological therapy and/or surgery has shown to be related to lower risks for 307 
mortality and PH-related events.(16, 24) These data further support the use of RVLS in 308 
clinical practice, as RVLS changes across time are associated to clinically relevant outcomes 309 
in PH patients. Future studies determining reference values and confirming clinically-relevant 310 
cut-off values are warranted to improve clinical decision-making and implementation of 311 
RVLS in practice.  312 
 313 
Limitations. The studies within this meta-analysis were non-uniform in design and varied in 314 
the inclusion criteria, methods to measure RVLS (intervendor and technique variabilities),  315 
follow-up periods and endpoints. We corrected for these between-study variation using a 316 
random effects model in our meta-analysis. Additionally to minimize the impact of 317 
intervendor and technique variability we reported the relative reduction of % of RVLS rather 318 
than absolute values. We also included studies which used RVFWS (n=7) and RVGLS (n=1) 319 
or both (n=3) to determine the predictive value of RVLS in PH patients. Unfortunately, the 320 
small amount of studies investigating RVGLS did not allow for a comparison between the 321 
predictive value of RVGLS and RVFWS. Similarly, we were not able to compare data 322 
obtained with 2D vs. 3D echocardiography and/or machines from different vendors. Due to 323 
differences in methodology and statistical approach, not all relevant studies could be included 324 
in our analysis. Studies using ROC-analysis(18, 20, 22, 25, 30), Kaplan Meier survival 325 
curves(18, 19, 22, 25), odds ratios (20) or predictive models (12, 13, 19) reported outcomes 326 
that align with the findings of the present meta-analysis.  327 
 328 
Conclusion. This systematic review and meta-analysis showed that RVLS possess 329 
independent prognostic value for a combined endpoint (HR: 1.22, 95%CI: 1.07-1.40) and all-330 
cause mortality (HR: 2.96, 95%CI: 2.00-4.38) in patients with PH. Collectively, these 331 
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findings emphasize that RVLS might be useful for optimizing current predictive models for 332 
morality or clinical events in PH patients. 333 
 334 
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Figure 1-Flow chart of study selection 488 
489 
  490 
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Figure 2-Forrest plot summarising the effect of a (relative) reduction of  RVLS on a 491 
combined endpoint of mortality and PH-related events in PH patients. The red squares present 492 
the weighted effect size and the black lines the 95%-CIs. The size of the red squares indicate 493 
the weight of the study. The black diamond presents the mean weighted HR. 494 
 495 
  496 
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Figure 3-Forrest plot summarising the effect of a (relative) reduction of  RVLS on all-cause 497 
mortality in PH patients. The red squares present the weighted effect size and the black lines 498 
the 95%-CIs. The size of the red squares indicate the weight of the study. The black diamond 499 
presents the mean weighted HR. 500 
501 
  502 
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Table 1. Inclusion and exclusion criteria 503 
 504 
  505 
Inclusion  Exclusion  
 
Population 
- Pulmonary hypertension - Animal studies 
- Paediatric studies 
 
Outcome Echocardiography 
- Right ventricular strain  
 
Outcome measures 
 
- Hazard ratio’s based on multivariate cox-
regression analysis 
- Receiver operating curves 
- Model based prediction 
 
Other 
- English language 
- Full papers 
- Language other than English 
- Abstract only 
- Conference proceedings  
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Table 2: Values of right ventricular longitudinal strain and hazard ratio’s extracted from the included studies 
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w
 
cu
t-o
ff v
alu
e 
D
ich
o
to
m
o
u
s 
C
o
n
tin
u
o
u
s 
Combined endpoint 
da Costa et al. (7) -27.5±2.4% -16.1±6.8%   < -14%  13% 4.66 (1.25-7.37) 1.53902 0.67132 
Fine et al. (8) -25.0±5.2% -19.6±6.6%    -6.7% 26% 1.27 (1.04-1.56) 0.23902 0.10343 
Giusca et al. (11)  -17.3±7.2%    -1% 6% 1.22 (0.92-1.62) 0.19885 0.14434 
Moceri et al. (29) † -14.1±3.6 -8.4±3.6%    -1% 12% 1.15 (0.95-1.40) 0.13976 0.09892 
Murata et al. (21)  -19.9±6.4%    -1% 5% 1.05 (0.97-1.15) 0.04879 0.04342 
Park et al. (10)  -16.1±5.0%    -5% 31% 2.09 (1.05-4.15) 0.75142 0.26639 
Unlu et al. (26)*  -16.6%#    -1% 5% 1.23 (1.04-1.45) 0.20701 0.08515 
All-cause mortality 
Haeck et al. (15)   -23.5±3.7% -14.0±3.5 < -19%  19% 3.40 (1.19-9.72) 1.22378 0.53577 
van Kessel et al. (9)   -24.8±4.0% -15.9±2.9 < -20%  19% 4.30 (1.11-16.61) 1.45861 0.69022 
Park et al. (10)  -16.1±5.0%    -5% 31% 2.08 (1.13-3.80) 0.73716 0.35059 
Sachdev et al. (23)  -15±5.0%    -5% 33% 2.00 (1.11-3.96) 0.69315 0.32446 
Vitarelli et al. (28) † -23.8±5.8 -18.8%#   < -17%  10% 4.60 (2.79-8.38) 1.52606 0.28056 
Symbols denote *=Inverse HR with respect to original article, †=3D strain analysis and #=mean value calculated from multiple groups. (RVLS=Right 
Ventricular Longitudinal Strain; HR=Hazard Ratio; SE=Standard Error) 
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Table 3: Population data extracted from the included studies 
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E
n
d
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o
in
t 
Combined endpoint 
da Costa et 
al. (7) 
NR N: 66 
Age: 45±15 
Female sex: 83% 
1 (n=66) 
 
 
 
I-II (67%) 
III (33%) 
Bosentan and ambrisentan (n=16) 
Sildenafil (n=31) 
Calcium channel blockers (n=2) 
Combined therapy (n=17) 
3.3y Cardiovascular mortality 
and hospitalization for 
worsening of PH 
Fine et al. 
(8) 
Prospective N: 406 
Age: 59±16 
Female sex: 65% 
1 (n=300) 
3 (n=58) 
4 (n=48) 
 
I (20%) 
II (34%) 
III (38%) 
IV (8%) 
Prostacyclin (n=50) 
Endothelin receptor antagonist (n=82) 
Phosphodiesterase-5 inhibitor (n=89) 
1.5y Cardiopulmonary death 
and cardiopulmonary 
events 
Giusca et 
al. (11) 
NR N: 32 
Age: 39±15 
Female sex: 69% 
1 (n=29) 
4 (n=3) 
II (40.6%) 
III (56.2%) 
IV (3.2%) 
Bosentan (n=11) 
Sildenafil (n=16) 
Combined (n=5) 
1.2y All-cause mortality and 
treatment failure 
Moceri et 
al. (29) † 
Prospective N: 104 
Age: 66±4 
Female sex: 56% 
1 (n=65) 
3 (n=26) 
4 (n=11) 
5 (n=2) 
II  (36.5%) 
III (44.2%) 
IV (19.3%) 
 
Advanced targeted PAH therapy (n=87) 0.6y PH related mortality 
Murata et 
al. (21) 
Retrospective N: 100 
Age: 51±17 
Female Sex:74% 
1 (n=72) 
4 (n=28) 
 
I (22%) 
II (46%) 
III (32%) 
Phosphodiesterase-5 inhibitor (n=69) 
Endothelin receptor antagonist (n=56) 
Prostacyclins (n=26) 
Calcium channel blockers (n=11) 
Vitamin K antagonist (n=28) 
1.2y All-cause mortality, 
hospitalization and 
intervention for 
deterioration right-sided 
heart-failure 
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Park et al. 
(10) 
Retrospective N: 51 
Age: 48±14 
Female sex: 78% 
1 (n=51) I (4%) 
II (61%) 
III (35%) 
Phosphodiesterase-5 inhibitor (n=29) 
Endothelin receptor antagonist (n=26) 
Prostacyclins (n=32) 
Calcium channel blockers (n=9) 
3.8y Clinical events 
Unlu et al. 
(26)* 
Retrospective N: 62 
Age: 61±15 
Female sex: 68% 
1 (n=33) 
4 (n=29) 
 
I (6.5%) 
II (25.8%) 
III (58%) 
IV (9.7%) 
Treatment naïve 3.8y All-cause mortality and 
heart or lung 
transplantation 
All-cause mortality 
Haeck et al. 
(15) 
Retrospective N: 142 
Age: 59±15 
Female sex: 63% 
1 (n=53) 
2 (n=46) 
3 (n=32) 
4 (n=7) 
5 (n=4) 
NR Endothelin receptor antagonist (n=37) 
Phosphodiesterase-5 inhibitor (n=19) 
Β-blocker (n=44) 
Angiotensin-converting-enzyme inhibitor/ 
angiotensin II receptor antagonist (n=58) 
Diuretics (n=91) 
Anticoagulation (n=64) 
2.6y All-cause mortality 
van Kessel 
et al. (9) 
Retrospective N: 53 
Age: 56±9 (n=25); 
54±17 (n=28) 
Female sex: 66% 
Mixed 
(n=53) 
 
 
II  (41.5%) 
III (41.5%) 
IV (9.4%) 
NR (7.%) 
Mono therapy (n=27) 
Double therapy (n=16) 
Triple therapy (n=8) 
2.3y All-cause mortality 
Park et al. 
(10) 
Retrospective N: 51 
Age: 48±14 
Female sex: 78% 
1 (n=51) 
 
I (4%) 
II (61%) 
III (35%) 
Phosphodiesterase-5 inhibitor (n=29 
Endothelin receptor antagonist (n=26) 
Prostacyclins (n=32) 
Calcium channel blockers (n=9) 
3.8y All-cause mortality 
Sachdev et 
al. (23) 
NR N: 80 
Age: 56±14 
Female sex: 76% 
1 (n=80) I-II  (28%) 
III (63%) 
IV (9%) 
Treatment naïve  2.0y All-cause mortality 
Vitarelli et 
al. (28) † 
NR N: 73 
Age: 53±13 
Female sex: 56% 
1 (n=25) 
2 (n=25) 
4 (n=23) 
I-II (71%) 
III-IV (29%) 
NR 2.0y All-cause mortality 
Symbols denote †=3D strain analysis. (WHO=World Health Organisation; NYHA=New York Heart Association; PH=Pulmonary Hypertension; 
NR=Not Reported) 
